Wall Street Analysts Claim We’re Not in an AI Bubble… Yet
20 minutes ago
Recent unusual trading patterns in the AI sector have sparked debates about a potential bubble, but several market experts insist this isn’t 1999—not just yet.
OpenAI plans to invest heavily in chips from Nvidia (NVDA) and Advanced Micro Devices (AMD). Interestingly, Nvidia has chosen to invest in OpenAI while also funding AMD. There’s a complex tapestry of relationships forming among chip manufacturers, cloud companies, and AI developers, highlighted by Nvidia’s investments in cloud providers Nebius (NBIS) and CoreWeave (CRWV), including an agreement to purchase chips and unused computing resources from CoreWeave by 2032.
Critics worry that these intertwined deals indicate the beginnings of an AI bubble. They argue that NVIDIA is inflating the perception of AI demand by financially backing firms that purchase and lease its chips.
However, many Wall Street analysts, including those from Bank of America and Goldman Sachs, dispute this bubble narrative in a memo issued on Wednesday.
Vivek Arya, a semiconductor analyst at BofA, pointed out, “We think worries over AI funding are quite overblown,” noting he expects circular trading to represent no more than 5% to 10% of the projected $5 trillion set to be spent on AI by 2030.
Read the full article here.
Acello Therapeutics Shares Surge Following Novo Nordisk Acquisition
41 minutes ago
Shares of Akero Therapeutics (AKRO) climbed nearly 20% in pre-market trading after Novo Nordisk (NVO), the Danish pharmaceutical giant, announced plans to acquire the company for as much as $5.2 billion.
Novo Nordisk revealed it will purchase Akero at $54 per share, which totals around $4.7 billion in cash, with additional contingent value rights amounting to $6 per share, or about $500 million.
Akero is working on a drug for metabolic dysfunction-associated steatohepatitis (MASH) named efluxifermin, which Novo Nordisk touts as potentially a game-changer in the field.
Novo Nordisk CEO Mike Doosder stated, “If approved, we think this drug could, on its own or combined with Wigovy (semaglutide), become a key treatment for one of the fastest-growing metabolic diseases today.”
At the outset of trading on Thursday, Akero shares had risen significantly, while Novo Nordisk’s U.S.-listed shares dipped by 30%.
Fed Officials Open to Rate Cuts, But Inflation Might Complicate Matters
1 hour 9 minutes ago
In a recent disclosure, Federal Reserve officials shared that they lowered the central bank’s key interest rate by a quarter point last month, despite ongoing inflation concerns.
The minutes from the Federal Open Market Committee reveal the tough choices policymakers face—balancing low inflation with high employment. Inflation continues to hover above the Fed’s 2% annual target, even as job growth has largely slowed.
Fed officials are considering a reduction in the federal funds rate to stimulate job growth but are also wary of maintaining it high to control inflation. The Fed’s interest rate has a significant impact on borrowing costs across various loans.
While markets expect the Fed to cut rates a couple more times this year, officials are carefully monitoring inflation, implying that any unexpected price hikes might disrupt these plans.
“Further rate cuts aren’t guaranteed since policymakers haven’t fully relinquished their focus on inflation,” commented David Russell, who heads global market strategy at TradeStation.
Read the full article here.
Stock Futures Stable After Significant S&P 500 and Nasdaq Declines
1 hour 31 minutes ago
Futures for the Dow Jones Industrial Average barely shifted, registering a rise of less than 0.1%.
S&P 500 futures remained largely unchanged.
Similarly, Nasdaq 100 futures experienced minimal changes.
